Symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction within  months of registration
Patients with myocardial infarction or unstable angina <  months prior to starting study drug
Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than  months before inclusion
Myocardial infarction or unstable angina pectoris within  months prior to randomization.
Severe/unstable angina pectoris, or myocardial infarction within  months prior to study entry
Acute myocardial infarction or angina pectoris.
Unstable angina pectoris or myocardial infarction ?  months prior to starting treatment in the study.
History of angina pectoris, symptomatic pericarditis, or myocardial infarction within  months prior to study entry;
mCRPC EXPANSION COHORT: Any of the following within  months before the first dose of study treatment:\r\n* Unstable angina pectoris\r\n* Stroke (including TIA, or other ischemic event)\r\n* Myocardial infarction
Unstable angina pectoris or acute myocardial infarction =<  months prior to starting study drug
Unstable angina pectoris or acute myocardial infarction =<  months prior to starting study drug
Have active angina pectoris or recent myocardial infarction (within  months).
Acute myocardial infarction or unstable angina pectoris <  months prior to Screening
Symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction within  months of enrollment
Any active angina or any unstable angina pectoris or myocardial infarction within one year of study entry
Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within  months
Angina pectoris =<  months prior to starting drug
Have active angina pectoris, stroke or recent myocardial infarction (within  months).
Arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) <  months prior to enrollment
Acute myocardial infarction or angina pectoris ?  months prior to starting study drug
Unstable angina pectoris or myocardial infarction ?  months prior to starting CC-.
Significant cardiac dysfunction; myocardial infarction within  months; unstable, poorly controlled angina pectoris.
Acute myocardial infarction or unstable angina pectoris <  months prior to Screening
History of angina pectoris, symptomatic pericarditis, or myocardial infarction within  months prior to study entry
Patients with myocardial infarction or unstable angina =<  months prior to starting study drug
Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within  months
Unstable angina pectoris or myocardial infarction less than  months prior to starting either study drug
Acute myocardial infarction (AMI) or unstable angina pectoris <  months prior to study entry
Unstable angina pectoris or myocardial infarction ?  months prior to starting CC
Patients with myocardial infarction or unstable angina =<  months prior to starting study drug
Acute myocardial infarction or angina pectoris ?  months prior to starting study drug
Patients with myocardial infarction or unstable angina ?  months prior to starting study drug.
Angina pectoris ?  months prior to starting study drug
Have active angina pectoris, stroke or recent myocardial infarction (within  months).
Subjects with any one of the following: ) Congestive heart failure, ) Myocardial infarction within  months prior to starting study treatment, ) Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
Angina pectoris ?  months prior to dosing with study drug
Acute myocardial infarction or angina pectoris ?  months prior to starting study drug
History of uncontrolled angina pectoris or myocardial infarction within  months prior to Screening;
